Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study

Current Diabetes Reports

Volumn 13, Issue 4, 2013, Pages 550-559

  Maahs, David M ^a,b   Caramori, Luiza ^c   Cherney, David Z I ^d   Galecki, Andrzej T ^e   Gao, Chuanyun ^f   Jalal, Diana ^b   Perkins, Bruce A ^d   Pop Busui, Rodica ^g   Rossing, Peter ^h,i,j   Mauer, Michael ^c   Doria, Alessandro ^k,l  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Joslin Clinic   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h STENO DIABETES CENTER   (Denmark)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k JOSLIN DIABETES CENTER   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Allopurinol; Diabetes; Diabetic kidney disease; Diabetic nephropathy; Glomerular filtration rate; Kidney disease; PERL trial; Randomized clinical trial; Type 1 diabetes; Uric acid

Indexed keywords

ALLOPURINOL; CREATININE; FEBUXOSTAT; PLACEBO; URIC ACID;

ARTICLE; BONE MARROW DEPRESSION; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CLEARANCE; KIDNEY FAILURE; LIVER TOXICITY; MACROALBUMINURIA; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; SKIN DEFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STUDY DESIGN; TOXIC EPIDERMAL NECROLYSIS; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; URIC ACID;

EID: 84880135111     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0381-0     Document Type: Article

References (81)

1. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia. 2012;55:2301-6.
2. Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307-16.
3. • Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol. 2012;32:407-14. Review highlighting the need for new strategies and novel therapeutics to prevent renal function decline.
4. Maahs DM, Rewers M. Editorial: mortality and renal disease in type 1 diabetes mellitus - progress made, more to be done. J Clin Endocrinol Metab. 2006;91:3757-9.
5. • de Boer I, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-9. Overview of prevalence of DKD in the US and demonstrates continued burden of diabetic kidney disease on individuals and its public health importance.
6. • Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011;22:545-53. Demonstrates persistence of ESRD risk despite advances in diabetes care in past decades.
7. •• Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes. Study. Nephrol Dial Transplant. 2010;25:1865-9. One of 3 epidemiologic studies from the PERL Consortium in which uric acid is associated with development of albuminuria over 6 years in young adults with type 1 diabetes.
8. •• Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58:1668-71. One of 3 epidemiologic studies from the PERL Consortium in which uric acid is associated with development of diabetic nephropathy over 18 years in an inception cohort of adults with type 1 diabetes.
9. •• Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33:1337-43. One of 3 epidemiologic studies from the PERL Consortium in which uric acid is associated with progressive renal function loss over 6 years in adults with type 1 diabetes.
10. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-97.
11. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-6.
12. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16:1909-19.
13. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Ren Physiol. 2002;282:F991-7.
14. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes. 2002;51:1118-24.
15. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
16. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-9.
17. • Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388-93. Clinical trial using allopurinol to lower uric acid to slow kidney and cardiovascular disease progression.
18. Krolewski AS, Warram JH. Epidemiology of late complications of diabetes: a basis for the development and evaluation of preventive program. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, editors. Joslin's diabetes mellitus. New York: Lippincott, Williams & Wilkins; 2005.
19. • Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58:1651-8. Large epidemiologic cohort study from Finland in which people with type 1 diabetes without evidence of diabetic kidney disease have similar standardized mortality rates compared with the general Finnish population.
20. • Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes. Complications Study. Diabetologia. 2010;53:2312-9. Extends the findings from the FinnDiane study [19] over 20 years in a US cohort with type 1 diabetes.
21. 2 in the DCCT-EDIC study.
22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.
23. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-6.
24. Wood J, Miller K, Maahs D, et al. Most youth with type 1 diabetes in the T1D exchange clinic registry do not meet ADA or ISPAD clinical guidelines. Diabetes Care. (in press).
25. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
26. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151:11-4.
27. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-7.
28. •• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012. In Press. Recent clinical trial highlighting the need for novel therapeutics to improve cardiorenal health in people with diabetes.
29. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727-36.
30. • Rodrigues TC, Maahs DM, Johnson RJ, et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care. 2010;33:2471-3. Epidemiologic study in which uric acid is associated with progression of subclinical coronary atherosclerosis in young adults with type 1 diabetes.
31. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003;26:2871-5.
32. McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications. 2008;22:18-23.
33. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:2019-24.
34. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55:1293-301.
35. Godsland IF, Johnston DG. Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. Metabolism. 2008;57:1190-7.
36. Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S165-8.
37. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol. 2011;31:459-65.
38. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75 Suppl 5:S13-6.
39. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21.
40. Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35:99-104.
41. • Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2-7. Post-hoc analysis suggesting losartan lowers uric acid as a mechanism of improving renal outcomes.
42. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642-50.
43. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16:791-9.
44. Zhang L, Zuo L, Xu G, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007;22:1093-9.
45. Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011;40:116-21.
46. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28:1234-42.
47. Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008;295:C1183-90.
48. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553-62.
49. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008;27:967-78.
50. Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33:298-304.
51. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-42.
52. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 2004;66:1465-70.
53. Myllymaki J, Honkanen T, Syrjanen J, et al. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant. 2005;20:89-95.
54. Netea MG, Kullberg BJ, Blok WL, Netea RT, Van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood. 1997;89:577-82.
55. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-40.
56. Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Ren Physiol. 2007;292:F116-22.
57. Doria A, Niewczas MA, Fiorina P. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol. 2012;32:437-44.
58. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-32.
59. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61.
60. Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat vs allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8.
61. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet. 2010;375:2161-7.
62. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20:182-7.
63. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746-51.
64. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-60.
65. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-7.
66. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26:3567-72.
67. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.
68. • Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704-9. Pharmacogenetic data in which the association of HLA-B*5801 is identified as an important risk factor for SJS.
69. Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res. 2012;64:256-61.
70. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute Of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003;42:617-22.
71. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036-40.
72. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18:1353-61.
73. Premaratne E, Macisaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 2008;31:971-3.
74. Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536-43.
75. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1569-76.
76. Mauer M, Drummond K. The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes. 2002;51:1572-9.
77. Gaspari F, Perico N, Matalone M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol. 1998;9:310-3.
78. O'Reilly PH, Brooman PJ, Martin PJ, Pollard AJ, Farah NB, Mason GC. Accuracy and reproducibility of a new contrast clearance method for the determination of glomerular filtration rate. BMJ (Clin Res Ed). 1986;293:234-6.
79. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int Suppl. 1997;63:S151-4.
80. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
81. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis. 2008;51:395-406.